Electronic Cigarette Use, Endothelial Dysfunction, Inflammation
Conditions
Brief summary
The use of electronic nicotine delivery systems, or e-cigarettes - colloquially referred to as vaping - in the United States has increased exponentially since their introduction to the US market in 2007. Prevalence of ever and current e-cigarette use is highest among teenagers and young adults with 16-28% of this population having reported vaping. While the majority of e-cigarette users are current tobacco smokers, 32.5% of current e-cigarette users are never- or former-smokers, representing a growing population of young adults who exclusively vape. While e-cigarettes have been marketed as a safer alternative to tobacco cigarettes, clinical studies examining these claims are limited. Cardiovascular disease (CVD) is the primary cause of premature death among tobacco cigarette smokers and reductions in vascular endothelial function, a significant predictor of future CVD, are detectible in otherwise healthy young adults who smoke. Despite the explosion in e-cigarette use among young adults, the health effects - especially the effects on mechanisms of vascular function - of these devices remain relatively unexplored. The purpose of this study is to directly asses the mechanistic role of inflammation in this dysfunction.
Interventions
DRUGPlacebo
Oral placebo tablet
DRUGSalsalate 750 MG Oral Tablet [DISALCID]
Oral salsalate tablet
Sponsors
University of Iowa
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 24 Years
Healthy volunteers
Yes
Inclusion criteria
* 18 - 24 years of age * no history of e-cigarette use (control) OR current with 6 months or more history of e-cigarette use (chronic use).
Exclusion criteria
* tobacco cigarette use (current or history of) * use of stimulant drugs * skin diseases * cardiovascular disease * diagnosed or suspected hepatic or metabolic disease including diabetes * statin or other cholesterol-lowering medication * antihypertensive medication * current pregnancy or breastfeeding * blood pressure greater than or equal to 140mmHg systolic and/or greater than or equal to 90mmHg diastolic * allergy to materials used during the experiment * known allergies to salsalate or other study drugs
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Microvascular endothelial function (Cutaneous conductance, %maximum) following salsalate treatment compared to placebo treatment | a total of 2 times throughout the study (approximately 4 weeks): 1) at the completion of 4 days of oral salsalate treatment, and 2) at the completion of 4 days of placebo treatment | Endothelium-dependent vasodilation assessed as cutaneous conductance response (cutaneous conductance = local red blood cell flux/mean arterial pressure; %maximum) to local heating of the skin (42 degrees Celcius). |
Countries
United States
Contacts
Primary ContactAnna Stanhewicz, PhD
Outcome results
None listed